Professional organizations are developing it
In Kcnj11 / islets, MDL-12330A abolished the amplifying effect of GIP, but only moderately reduced the response to GLP-1 (Figure 3A)
That slows your metabolism and causes symptoms like weight gain, fatigue, cold sensitivity, constipation, and brain fog
Because its both a GLP-1 and GIP, tirzepatide serves as a greater appetite suppressor than semaglutide
"BPC" stands for "Body Protection Compound." In preclinical work it is proposed to act through several overlapping pathways, including promotion of new blood-vessel growth (angiogenesis), modulation of nitric-oxide signaling, and anti-inflammatory activity, rather than through one well-defined receptor mechanism the way a conventional small-molecule drug does